Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
All prior quarters are free. How to browse earnings-call scores without Pro. How to read a company earnings-call score.
Full Pro access for 30 days when you create a free account. No credit card required.
Calendar quarter Q2 2026Earnings call Jul 30, 2026 · most recent call
REGN’s newest analyzed quarter is part of Tellvest Pro: its score, breakdown, narrative and analyst Q&A. Every prior quarter is free.
Sources. Scores: Regeneron Pharmaceuticals’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: REGN daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
The breakdown for this quarter is part of Tellvest Pro.
On October 1, 2026, Regeneron and Sanofi signed a Sixth Amendment to their antibody collaboration to co-develop and co-commercialize four new long-acting Regeneron antibodies (IL-13, IL-4, IL-4Rα, IL-4xIL-13), sharing global profits equally. Sanofi will pay $1.0 billion upfront plus up to $7.0 billion in milestones. Regeneron agreed to dismiss its lawsuit over access to Dupixent commercialization information. It expects a ~$22 million acquired IPR&D charge in Q3 2026 (~$0.18 per diluted share).
What each event means for REGN’s sentiment score is part of Tellvest Pro.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $3.79B | +10.3% | $8.06 | -20.9% | 26.1% | 24.2% | $996M |
| FY2025 Q1 | $3.03B | -3.7% | $7.27 | +15.9% | 19.5% | 26.7% | $774M |
| FY2025 Q2 | $3.68B | +3.6% | $12.81 | +3.2% | 29.4% | 37.9% | $968M |
| FY2025 Q3 | $3.75B | +0.9% | $13.62 | +18.0% | 27.3% | 38.9% | $1.42B |
| FY2025 Q4 | $3.88B | +2.5% | $7.86 | -2.5% | 22.7% | 21.7% | $922M |
| FY2026 Q1 | $3.61B | +19.0% | $6.75 | -7.2% | 17.8% | 20.2% | $848M |
| FY2026 Q2Selected | $4.29B | +16.7% | $12.23 | -4.5% | 30.1% | 30.2% | $573M |
Management-stated figures from REGN’s newest call are part of Tellvest Pro.